DDInter298 DDInter875
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of [cisplatin] with reduced nephrotoxicity and vomiting.[A230463,A230523] Carboplatin was granted FDA approval on 3 March 1989.
Human papillomavirus type 11 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection. It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae* and self-assembled into VLPs.
Carboplatin {u} (Compound) treats {v} (Disease) esophageal cancer
Carboplatin {u} (Compound) binds {v} (Gene) GSTM1
Carboplatin {u} (Compound) is included by {v} (Pharmacologic Class) Platinum-containing Compounds
Carboplatin {u} (Compound) causes {v} (Side Effect) Venous thrombosis
Carboplatin (Compound) treats esophageal cancer (Disease)
Carboplatin (Compound) binds GSTM1 (Gene)
Carboplatin (Compound) is included by Platinum-containing Compounds (Pharmacologic Class)
Carboplatin (Compound) causes Venous thrombosis (Side Effect)